News Laboratorios Farmaceuticos Rovi, S.A. OTC Markets

Stocks

LABFF

ES0157261019

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:50:50 26/11/24 am AEDT			5-day change	1st Jan Change
65.86 ^USD	-27.31%		-.--%	-

23/07	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
23/07	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

All News

Mentions Relevance

23/07	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
23/07	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
23/07	Laboratorios Farmaceuticos Rovi, S.A. Maintains Earnings Guidance for 2026	CI
23/07	Laboratorios Farmaceuticos Rovi S A : First half 2026 results press release	PU
08/07	Laboratorios Farmaceuticos Rovi S A : ROVI and the Regional Government of Castilla-La Mancha promote a framework of collaboration to modernise healthcare services through technological innovation	PU
09/05	Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026
07/05	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
06/05	Laboratorios Farmaceuticos Rovi, S.A. Updates Earnings Guidance for the Full Year 2026	CI
06/05	Rovi Q1 net profit at 9.4 mln euros	RE
06/05	Rovi expects risperidone to reach potential sales of 100-200 mln euros globally over next few years	RE
06/05	Laboratorios Farmaceuticos Rovi S A : First three months of 2026 results press release	PU
01/04	Rovi closes deal to buy pharmaceutical manufacturing facility in US	RE
26/02	Laboratorios Farmaceuticos Rovi, S.A., 2025 Earnings Call, Feb 25, 2026
26/02	Pharmaceutical Company Rovi Increases Net Profit Thanks to Okedi and Heparin Sales	RE
25/02	Drugmaker Rovi's net profit rises on higher Okedi, heparin sales	RE
25/02	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25/02	Laboratorios Farmaceuticos Rovi, S.A. Provides Earnings Guidance for the Fiscal Year 2026	CI
25/02	ROVI Proposes Dividend Distribution for the Year 2025	CI
25/02	Laboratorios Farmaceuticos Rovi S A : 2025 results press release	PU
25/02	Rovi to propose dividend of 0.9594 eur/shr	RE
25/02	Rovi FY Ebitda 216.2 mln euros	RE
25/02	Rovi FY net profit at 140.4 mln euros	RE
18/11	Rovi and Roche sign final agreement for manufacture of new medicine	RE
18/11	Laboratorios Farmaceuticos Rovi S A : ROVI releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development	PU
06/11	Rovi sees 2026 operating revenue to increase by up to low double-digit percentage vs 2025	RE